Want to join the conversation?
$ABBV 2Q15 Call: Adjusted earnings per share of a dollar $0.08, representing a growth of more than 31% vs. 2Q14. Our results included strong operational sales growth of nearly 20% driven by a number of products across our portfolio, including strong performance from our newly acquired oncology therapy Imbruvica.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?